Capecitabine/bevacizumab compared
to capecitabine alone in pretreated metastatic breast cancer:
Results of a Phase III study. Clin Breast Cancer
2003;3(6):375-7.
Ahn Sr J et al. Phase II study of a combination
chemotherapy of capecitabine and vinorelbine in metastatic
breast cancer with previous exposure to anthracycline and
taxane: Preliminary results. Proc ASCO 2002: Abstract
2030.
Andres R et al. Capecitabine plus gemcitabine is
an active combination for patients with metastatic breast
cancer refractory to anthracyclines and taxanes. Proc
ASCO 2003;Abstract
356.
Bauer-Kosinska B et al. Capecitabine monotherapy
in the treatment of patients with chemotherapy pre-treated
metastatic breast cancer. Proc ASCO 2003;Abstract
320.
Biganzoli L et al. Moving forward with capecitabine:
A glimpse of the future. Oncologist 2002;7(Suppl
6):29-35. Abstract.
Blum J. The role of capecitabine, an oral, enzymatically
activated fluoropyrimidine, in the treatment of metastatic
breast cancer. Oncologist 2001;6(1):56-64. Abstract.
Chan S et al. A phase II study on an all-oral regimen
of capecitabine (XelodaTM) (X), idarubicin (I) and cyclophosphamide
(C) (XIC) for metastatic breast cancer — Safety,
efficacy and quality of life. Proc ASCO 2002:
Abstract
2023.
Crown J. Nonanthracycline containing docetaxel-based
combinations in metastatic breast cancer. Oncologist
2001;6(Suppl 3):17-21. Abstract.
Fumoleau P et al. Capecitabine (Xeloda) in patients
with advanced breast cancer (ABC), previously treated with
anthracyclines and taxanes: Results of a large phase II
study. Proc ASCO 2002: Abstract
247.
Ghosn M et al. Vinorelbine (Navelbine) IV and capecitabine
(VINOCAP) as front line chemotherapy in metastatic breast
cancer (MBC). Proc ASCO 2002: Abstract
1978.
Gligorov J et al. Capecitabine and oral vinorelbine
in metastatic breast cancer: Preliminary experience. Proc
ASCO 2003;Abstract
351.
Kaklamani VG, Gradishar WJ. Role of capecitabine
(Xeloda) in breast cancer. Expert Rev Anticancer
Ther 2003;3(2):137-44. Abstract.
Lago S et al. Quality of life (QoL) in metastatic
breast cancer (MBC) patients taking capecitabine. Proc
ASCO 2003;Abstract
2994.
Leonard RC et al. Capecitabine named-patient programme
for patients with advanced breast cancer. The UK experience. Eur
J Cancer 2002;38(15):2020-4. Abstract.
Maher JF, Villalona-Calero MA. Taxanes and capecitabine
in combination: Rationale and clinical results. Clin
Breast Cancer 2002;2(4):287-93. Abstract.
Miles D et al. Combination versus sequential single-agent
therapy in metastatic breast cancer. Oncologist
2002;7(Suppl 6):13-9. Abstract.
O'Shaughnessy J. Capecitabine and docetaxel in
advanced breast cancer: Analyses of a phase III comparative
trial. Oncology (Huntingt) 2002;16(10 Suppl 12):17-22.
Abstract.
O'Shaughnessy J. Clinical experience of capecitabine
in metastatic breast cancer. Eur J Cancer 2002;38(Suppl
2):10-4. Abstract.
O'Shaughnessy JA et al. Randomized, open-label,
phase II trial of oral capecitabine (Xeloda) vs a reference
arm of intravenous CMF (cyclophosphamide, methotrexate
and 5-fluorouracil) as first-line therapy for advanced/metastatic
breast cancer. Ann Oncol 2001;12(9):1247-54. Abstract.
O'Shaughnessy J et al. Superior survival with capecitabine
plus docetaxel combination therapy in anthracycline-pretreated
patients with advanced breast cancer: Phase III trial results. J
Clin Oncol 2002;20(12):2812-23. Abstract.
O'Shaughnessy J et al. Treatment for anthracycline-pretreated
metastatic breast cancer. Oncologist 2002;7(Suppl
6):4-12. Abstract.
Procopio G et al. A Phase II study of capecitabine
in elderly patients with advanced breast cancer. Proc
ASCO 2001:Abstract
3134.
Procopio G et al. Safety and activity of capecitabine
in elderly patients (pts) with advanced breast cancer (ABC). Proc
ASCO 2003;Abstract
3050.
Scarfe AG et al. Interim results of a phase II
study of weekly docetaxel (Taxotere®) combined with
intermittent capecitabine (Xeloda®) for patients with
anthracycline pretreated metastatic breast cancer. Proc
ASCO 2002:Abstract
1984.
Seidman AD. Monotherapy options in the management
of metastatic breast cancer. Semin Oncol 2003
Apr;30(2 Suppl 3):6-10. Abstract.
Seidman AD et al. Single-agent capecitabine: A
reference treatment for taxane-pretreated metastatic breast
cancer? Oncologist 2002;7(Suppl 6):20-8. Abstract.
Semiglazov TY et al. Oral capecitabine (Xeloda)
in the treatment of anthracycline-refractory, anthracycline
and docetaxel-refractory metastatic breast cancer (MBC). Proc
ASCO 2002: Abstract
2061.
Soto C et al. Capecitabine (X) plus docetaxel (T)
vs capecitabine plus paclitaxel (P) vs sequential capecitabine
then taxane in anthracycline pretreated patients (pts)
with metastatic breast cancer: Early results. Proc
ASCO 2003;Abstract
28.
Talbot DC et al. Randomised, phase II trial comparing
oral capecitabine (Xeloda) with paclitaxel in patients
with metastatic/advanced breast cancer pretreated with
anthracyclines. Br J Cancer 2002;86(9):1367-72.
Abstract.
Venturini M et al. Capecitabine in combination
with docetaxel and epirubicin in patients with previously
untreated, advanced breast carcinoma. Cancer 2003;97(5):1174-80.
Abstract.
Wagstaff AJ et al. Capecitabine: A review of its
pharmacology and therapeutic efficacy in the management
of advanced breast cancer. Drugs 2003;63(2):217-36.
Abstract.
Wilke H. Future treatment options with capecitabine
in solid tumours. Eur J Cancer 2002;38 (Suppl
2):21-5. Abstract.
|
